Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

IntelGenx Technologies Corp. Security Holders Approved the Amendment of the 2006 Stock Option Plan

T.IGX
IntelGenx Technologies Corp. Security Holders Approved the Amendment of the 2006 Stock Option Plan

Saint Laurent, Quebec--(Newsfile Corp. - May 9, 2013) - IntelGenx Technologies Corp. (TSXV: IGX) (OTCQX: IGXT) ("IntelGenx" or the "Company") announced today that at the Company's Annual General Meeting on May 7, 2013, the Security Holders of the Company approved to amend the 2006 Stock Option Plan to increase the number of shares available for issuance under the Plan from 3,308,127 to 5,030,292 or 10% of the Company's issued and outstanding shares as of the record day. The amendment of the Plan is subject to TSX-Venture approval.

About IntelGenx:

IntelGenx is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. IntelGenx uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastrointestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. IntelGenx' development pipeline includes products for the treatment of indications such as severe depression, hypertension, erectile dysfunction, migraine, insomnia, CNS indications, idiopathic pulmonary fibrosis, oncology and pain, as well as animal health products. More information is available about the company at www.intelgenx.com.

CONTACT INFORMATION

IntelGenx Technologies Corp.
Ingrid Zerbe
Corporate Secretary
T: 514-331-7440 (ext. 202)
F: 514-331-0436
ingrid@IntelGenx.com
www.intelgenx.com

Each of the TSX Venture Exchange and OTCQX has neither approved nor disapproved the contents of this press release.